The proportion of individuals testing positive for ADA against adalimumab was higher than previously reported (5, 6, 14); this is consistent with the increased sensitivity of the drug-tolerant ADA assay (4), and may also reflect lower levels of cotherapy with immunosuppressants such as methotrexate in psoriasis compared with other IMIDs. The gene discussed is ADA; the disease is psoriasis.